oral apelin receptor GPCR agonist

completed Ph. I for heart failure, discontinued

from cell-based HTS and opt.

J. Med. Chem., Mar. 19, 2021

Bristol Myers Squibb, Princeton, NJ

APJ-compound-14

The Bristol Myers Squibb apelin receptor (APJ) GPCR agonist (“compound 14”) is a clinical candidate for heart failure which completed a Ph. I study. Endogenous pyroglutamated apelin-13 peptide has…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: